343
Views
7
CrossRef citations to date
0
Altmetric
Guest Editorial/Misafir Editoryal

Novel Targets for Development of Drugs for Treating Schizophrenia: Focus on Glycine, D-Serine and Nitric Oxide

, , , , , & show all
Pages 129-137 | Published online: 08 Nov 2016
 

ABSTRACT

For many years the focus of neurochemical and pharmacological studies on schizophrenia was on dopamine, and that work yielded a great deal of information about the possible etiology of this debilitating disorder and contributed significantly to the development of antipsychotic drugs. However, it has become increasingly apparent that other neurotransmitters and neuromodulators must also play an important role, and in recent years there has been considerable interest in these other compounds and the systems related to them in the search for developing drugs that are more effective and have fewer side effects than the antipsychotics currently available. This review deals with three of those neurochemicals, namely glycine, D-serine and nitric oxide, and shows how an increased knowledge of them may be important in the future diagnosis and/or pharmacotherapy of schizophrenia.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.